File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women

TitleEfficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women
Authors
Issue Date2003
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal Of Clinical Endocrinology And Metabolism, 2003, v. 88 n. 7, p. 3130-3136 How to Cite?
AbstractIn healthy Caucasian postmenopausal women, raloxifene increases bone mineral density (BMD), decreases biochemical markers of bone turnover, and lowers low-density lipoprotein (LDL) cholesterol, without effects on high-density lipoprotein (HDL) cholesterol and triglycerides. This randomized, double-blind study examines the effects of raloxifene 60 mg/d (n = 483) or placebo (n = 485) in healthy postmenopausal Asian women (mean age 57 yr) from Australia, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, Taiwan, and Thailand. Serum osteocalcin, serum N-telopeptide, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were assessed at baseline and 6 months. Lumbar spine BMD was measured at baseline and 1 yr in 309 women from 4 countries. Clinical adverse events were recorded at each interim visit. At 6 months, raloxifene 60 mg/d significantly decreased osteocalcin, N-telopeptide, total cholesterol, and LDL cholesterol by medians of 15.9%, 14.6%, 5.3%, and 7.7%, respectively, from placebo. Changes in HDL cholesterol and triglycerides were similar between raloxifene and placebo. Raloxifene 60 mg/d increased mean lumbar spine BMD (1.9%) from placebo at 1 yr (P = 0.0003). The incidences of hot flashes (placebo 3.5%, raloxifene 5.6%, P = 0.12), and leg cramps (placebo 2.7%, raloxifene 4.3%, P = 0.16) were not different between groups. No case of venous thromboembolism was reported. The effects of raloxifene 60 mg/d on bone turnover, BMD, and serum lipids in healthy postmenopausal Asian women were similar to that previously reported in Caucasian women.
Persistent Identifierhttp://hdl.handle.net/10722/77987
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorChao, HTen_HK
dc.contributor.authorHuang, KEen_HK
dc.contributor.authorNeed, AGen_HK
dc.contributor.authorTaechakraichana, Nen_HK
dc.contributor.authorLoh, FHen_HK
dc.contributor.authorGonzaga, Fen_HK
dc.contributor.authorSriram, Uen_HK
dc.contributor.authorIsmail, NMNen_HK
dc.contributor.authorFarooqi, Aen_HK
dc.contributor.authorRachman, IAen_HK
dc.contributor.authorCrans, GGen_HK
dc.contributor.authorWong, Men_HK
dc.contributor.authorThiebaud, Den_HK
dc.date.accessioned2010-09-06T07:37:56Z-
dc.date.available2010-09-06T07:37:56Z-
dc.date.issued2003en_HK
dc.identifier.citationJournal Of Clinical Endocrinology And Metabolism, 2003, v. 88 n. 7, p. 3130-3136en_HK
dc.identifier.issn0021-972Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/77987-
dc.description.abstractIn healthy Caucasian postmenopausal women, raloxifene increases bone mineral density (BMD), decreases biochemical markers of bone turnover, and lowers low-density lipoprotein (LDL) cholesterol, without effects on high-density lipoprotein (HDL) cholesterol and triglycerides. This randomized, double-blind study examines the effects of raloxifene 60 mg/d (n = 483) or placebo (n = 485) in healthy postmenopausal Asian women (mean age 57 yr) from Australia, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, Taiwan, and Thailand. Serum osteocalcin, serum N-telopeptide, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were assessed at baseline and 6 months. Lumbar spine BMD was measured at baseline and 1 yr in 309 women from 4 countries. Clinical adverse events were recorded at each interim visit. At 6 months, raloxifene 60 mg/d significantly decreased osteocalcin, N-telopeptide, total cholesterol, and LDL cholesterol by medians of 15.9%, 14.6%, 5.3%, and 7.7%, respectively, from placebo. Changes in HDL cholesterol and triglycerides were similar between raloxifene and placebo. Raloxifene 60 mg/d increased mean lumbar spine BMD (1.9%) from placebo at 1 yr (P = 0.0003). The incidences of hot flashes (placebo 3.5%, raloxifene 5.6%, P = 0.12), and leg cramps (placebo 2.7%, raloxifene 4.3%, P = 0.16) were not different between groups. No case of venous thromboembolism was reported. The effects of raloxifene 60 mg/d on bone turnover, BMD, and serum lipids in healthy postmenopausal Asian women were similar to that previously reported in Caucasian women.en_HK
dc.languageengen_HK
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_HK
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_HK
dc.rightsJournal of Clinical Endocrinology and Metabolism. Copyright © The Endocrine Society.en_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshBone Density - drug effectsen_HK
dc.subject.meshCholesterol, HDL - blooden_HK
dc.subject.meshCholesterol, LDL - blooden_HK
dc.subject.meshEstrogen Antagonists - administration & dosage - adverse effectsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLumbar Vertebraeen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOsteoporosis - ethnology - prevention & controlen_HK
dc.subject.meshPostmenopauseen_HK
dc.subject.meshRaloxifene - administration & dosage - adverse effectsen_HK
dc.subject.meshTriglycerides - blooden_HK
dc.titleEfficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian womenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0021-972X&volume=88&issue=7&spage=3130&epage=3136&date=2003&atitle=Efficacy+and+safety+of+raloxifene+60+milligrams/day+in+postmenopausal+Asian+womenen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1210/jc.2002-021855en_HK
dc.identifier.pmid12843154-
dc.identifier.scopuseid_2-s2.0-0037622815en_HK
dc.identifier.hkuros88448en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037622815&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume88en_HK
dc.identifier.issue7en_HK
dc.identifier.spage3130en_HK
dc.identifier.epage3136en_HK
dc.identifier.isiWOS:000183926300027-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK
dc.identifier.scopusauthoridChao, HT=7202973736en_HK
dc.identifier.scopusauthoridHuang, KE=7403188155en_HK
dc.identifier.scopusauthoridNeed, AG=35918054900en_HK
dc.identifier.scopusauthoridTaechakraichana, N=7003394053en_HK
dc.identifier.scopusauthoridLoh, FH=7006427916en_HK
dc.identifier.scopusauthoridGonzaga, F=6603474158en_HK
dc.identifier.scopusauthoridSriram, U=6603033368en_HK
dc.identifier.scopusauthoridIsmail, NMN=35918276400en_HK
dc.identifier.scopusauthoridFarooqi, A=7005717062en_HK
dc.identifier.scopusauthoridRachman, IA=12787433800en_HK
dc.identifier.scopusauthoridCrans, GG=6507663421en_HK
dc.identifier.scopusauthoridWong, M=7403906291en_HK
dc.identifier.scopusauthoridThiebaud, D=7005184974en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats